Pegtibatinase not checked
Travere Therapeutics, Inc. · OT-58 · TVT-058
FollowEvery change as it happens, and a Monday email
Trials
3 active
3 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Homocystinuria (3 trials)
- Main trialPhase 3
- “Researchers are looking for a better way to treat people living with classical homocystinuria (HCU), a rare inherited condition. It is caused by changes in the cystathionine beta-synthase (or "CBS") gene and prevents an enzyme from working correctly in the body. This enzyme helps break down homocysteine, which is produced when the body processes methionine from protein-containing foods. This helps keep homocysteine and methionine at healthy levels. When this enzyme is not working, homocysteine and methionine build up in the blood and then spread into different tissues of the body and stop…”In the company’s words, NCT06247085 on ClinicalTrials.gov
- Other names
- OT-58 · TVT-058 · OT-058
Coming up3
- Jul 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Aug 2027Phase 3 trial completes · ClinicalTrials.gov
- Aug 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Aug 2027 | Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment | |
| Phase 3Enrolling by invitation | Aug 2030 | A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) (ENSEMBLE) | |
| Phase 1/2Recruiting | Jul 2027 | Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026